Sino Biopharmaceutical Ltd, shortly Sino Biopharm, is the first business that is listed among the leading biotech companies in Hong Kong. It is a civilian-run enterprise with a range of subsidiaries, which specializes in the therapeutic areas of oncology, hepatology and respiratory and surgery. This company operates as a research and development pharmaceutical corporation. These subsidiaries are situated in Beijing, Shanghai, Nanjing, Lianyungang, Qingdao as well as other places, and have multiple manufacturing locations.

As a member of Charoen Pokphand Group and headquartered in Hong Kong and Beijing, Sino Biopharm has strong producing capabilities and broad patients access across China. It principally takes part in researching, developing, manufacturing and selling biopharmaceutical products for the medical treatment. There are a lot of diseases that these biopharmaceutical products are used to prescribe a treatment like ophthalmia, hepatitis... Moreover, it also participates in other minor businesses through its branches, such as properties, health food, optical glass, optical and auditory products.

Sino Biopharm is committed to innovating to address unmet healthcare demands worldwide. It has been listed in the "Top 50 Global Pharmaceutical Enterprises" announced by the authoritative American magazine Pharmaceutical Director for four successive years. Besides, it also has been ranked as the "Top 50 Best Companies in Asia Pacific" by Forbes (Asia) for three consecutive years.

Founded: 2000

Headquarters: Wan Chai, Hong Kong

Website: https://www.sinobiopharm.com/en/

HUTCHMED Ltd is the next name that is known as the leading biotech company in Hong Kong. It was formerly called Hutchison China MediTech Limited and changed its name to HUTCHMED Ltd in May 2021. It is one of the first global-focused novel drug discovery companies in China. The company was incorporated in 2000 and its headquarter is in Central, Hong Kong.

HUTCHMED is among the first global-focused novel drug discovery companies in China. It is divided into two reported segments including oncology, immunology, and other ventures. Over the past two decades, this company has established a completely integrated R&D platform with world-class discovery and development capabilities. Since its establishment, it has built up 13 cancer drug candidates from internal discovery into clinical studies across the globe, with the first three oncology drugs currently accepted and marketed.

HUTCHMED is an innovative and commercial-stage biopharmaceutical institution. It constantly discovers, enhances, and commercializes aimed cure and immunotherapies for cancer and immunological diseases in both HongKong and overseas. Thanks to this, over 1,300 staffs have developed ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and launched. This organization also has a portfolio of several cancer drug candidates currently in clinical studies across the globe and extensive commercial infrastructure in its home market.

Founded: 2000

Headquarters: Central, Hong Kong

Website: https://www.hutch-med.com/

Coming third in the list of largest biotech companies in Hong Kong is CK Life Sciences Int'l., (Holdings), Inc., or CK Life Sciences. It is an investment holding business and a branch of CK Hutchison Holdings. It was founded in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002, then it was transferred to Main Board of the Hong Kong Stock Exchange in 2008.

As a biotech company specializing in pharmaceutics, CK Life Sciences carries out researching, developing, manufacturing, commercializing, marketing, and selling health and agriculture-related products in the Asia Pacific and North America. It is organized through three business segments, comprising Agriculture Related, Health and Investment. It also fosters treatment methods for cancer, health supplements, natural healthcare products, fertilizer goods and crop protection items. In addition, this company also manufactures eco-fertilizer products and nutritional supplements, mostly divided into two main categories like Environment and Health.

CK Life Sciences continuously supports good health and sustainable growth in its company and other businesses. It currently operates in a variety of other nations including Australia, Canada, China, US and Virgin Islands.

Founded: 2000

Headquarters: Tai Po Industrial Estate, Hong Kong

Website: https://www.ck-lifesciences.com/

SinoMab BioScience Ltd, or SinoMab, is a Hong Kong based clinical-phase biotech company. It was established in 2001 and is headquartered in Pak Shek Kok, Hong Kong. This company operates in various locations comprising Mainland China, the Cayman Islands, and Hong Kong.

Known as a biopharmaceutical company, SinoMab takes part in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. It usually focuses on the development of new and high-value recombinant therapeutic proteins for treating different life-threatening and hindering diseases in human. Its leading product is SM03, a first-in-target anti-CD22 mAb, which is not only in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), but also in a variety of clinical stages for other immunological diseases, including systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL).

In addition to that, SinoMab also pay attention to make progress SN1011, a Bruton's tyrosine kinase inhibitor. This is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage include SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA.

Founded: 2001

Headquarters: HK Science Park, Pak Shek Kok,, HK

Website: https://www.sinomab.com/

China Regenerative Medicine International Ltd (CRMI), an investment holding company, is one of the top biotech companies in Hong Kong. It was formerly known as China Bio-Med Regeneration Technology Ltd and then renamed to China Regenerative Medicine International Ltd (CRMI) in March 2015. It was set up in 1995 and is headquartered in Tsim Sha Tsui, Hong Kong. It principally participates in R&D, production and distribution of bio-medical and healthcare products, consists of Cellular Therapy, Tissue Engineering Bio-Medical Devices, Cosmetics & Healthcare Products, Medical Equipment & Other Services.

CRMI engages in the research and development of bio-medical and healthcare products, as well as medical techniques. It is organized through Cell Products and Services, Cosmetic Products and Services, and Healthcare Products and Services segments. This company brings to its clients health management services comprising assessment of health situation, treatment for detox, balance of inner body, nourishing organs, and enhancement of immune system; and beauty services comprising non-surgical medical aesthetic services, basic skincare, solutions for youthful skin, hair revitalizing, lines firming, partial remodelling, and intimate repairing services. Besides that, skincare and cosmetic products, including facial and eye creams, serums, moisturizing spray, tonic water, etc., are also provided under the Ascara brand.

With a view to improving human health, CRMI noticeably pay close attention to the demands of patients, and improve modern high technology to benefit the public, so as to meet the customers' expectations.

Founded: 2001

Headquarters: Tsim Sha Tsui, Hong Kong

Website: http://www.crmi.hk

Gallant BioTechnology Limited (GBT) is a licensed biotech company in Hong Kong with a manufacturing principle in China.

As a crucial institution in fostering the development of biotech manufacturing, Gallant Biotech provides a wide range of services to corporations and customers. Aside from being a raw material donor and an original equipment producer (OEM), Gallant Biotech is also in charge of experimental work for organizations looking to outsource. This company also manufactures its own dietary supplements and skincare products. It is apparent that Gallant Biotech takes advantage of the potential of biotechnology and natural resources to create scientific innovations that improve the human's health.

As one of the leading biotech manufacturing companies, Gallant Biotech has made a contribution to a mass of research and development projects in both Hong Kong and China, ranging from DNA authentication on TCM, protecting skin care materials, and Herbochips molecular drug concealing to environmental microbial supervising. It also has fostered several partnerships with prestigious brands, consisting of Hong Kong Chinese Medicine Merchants Association, Watsons Hong Kong, and Yunnan Baiyao.

Founded: 1977
Headquarters: Causeway Bay, Hong Kong
Website: https://www.gallantbiotech.com/en/